Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events
-
Published:2023-12
Issue:
Volume:
Page:
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Nizam AmandaORCID,
Rader Ryan K.,
Tzeng AliceORCID,
Wei WeiORCID,
Sheng Iris Yeong-Fung,
Martin Allison,
Wee Christopher E.ORCID,
Gilligan Timothy D.ORCID,
Gupta Shilpa,
Ornstein Moshe C.ORCID
Reference36 articles.
1. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023
2. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature;Mari;World J Urol,2018
3. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet North Am Ed,2016
4. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial;Sharma;Lancet Oncol,2017
5. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献